<p>A fresh analyst upgrade and encouraging clinical data are strengthening the case for pemvidutide and the future of liver health. The first wave of GLP-1 drugs changed the conversation around obesity. They helped people eat less and lose weight, but they also raised a bigger question: what comes next</p>